Calliditas Therapeutics’ nomination committee for the AGM 2022 November 2, 2021 10:00 CET Regulatory Read more
Updated regulatory timeline for review of MAA in Europe. September 16, 2021 14:30 CET Regulatory Read more
PDUFA goal date extension for Nefecon NDA in the U.S. September 14, 2021 21:10 CET Regulatory Read more
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million August 12, 2021 23:55 CET Regulatory Read more
Calliditas Therapeutics intends to carry out a directed share issue August 12, 2021 17:04 CET Regulatory Read more
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe July 21, 2021 08:45 CET Regulatory Read more
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency May 28, 2021 14:40 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 27, 2021 18:30 CET Regulatory Read more
FDA grants priority review for Nefecon, for patients with IgA nephropathy April 28, 2021 09:50 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 26, 2021 12:00 CET Regulatory Read more
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy April 23, 2021 08:30 CET Regulatory Read more
Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy March 15, 2021 07:30 CET Regulatory Read more
Calliditas announces termination of the proposed global offering January 28, 2021 14:40 CET Regulatory Read more
Calliditas Therapeutics launches proposed global offering January 26, 2021 22:10 CET Regulatory Read more
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day January 20, 2021 08:00 CET Regulatory Read more